NASDAQ:CABA - Get Free Report )'s share price traded down 8.7% on Thursday . The company traded as low as $11.77 and last traded at $11.83. 215,297 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 931,581 shares. The stock had previously closed at $12.96.
Get Cabaletta Bio alerts:
Sign Up
Analyst Ratings Changes A number of research analysts have recently commented on CABA shares. Cantor Fitzgerald reiterated an "overweight" rating and set a $50.00 price target on shares of Cabaletta Bio in a report on Friday, April 5th. Citigroup lifted their target price on Cabaletta Bio from $26.00 to $30.00 and gave the stock a "buy" rating in a research report on Thursday, April 4th. Wells Fargo & Company increased their price objective on shares of Cabaletta Bio from $34.00 to $35.00 and gave the company an "overweight" rating in a research note on Friday, March 22nd. Jefferies Financial Group started coverage on Cabaletta Bio in a research note on Monday, February 5th. They issued a "buy" rating and a $36.00 price target on the stock. Finally, HC Wainwright lifted their target price on shares of Cabaletta Bio from $25.00 to $30.00 and gave the company a "buy" rating in a research note on Friday, March 22nd. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, Cabaletta Bio has a consensus rating of "Buy" and an average target price of $34.33.
Check Out Our Latest Stock Analysis on CABA
Cabaletta Bio Stock Performance The company has a fifty day moving average price of $18.96 and a two-hundred day moving average price of $18.92. The company has a market cap of $587.56 million, a P/E ratio of -7.28 and a beta of 2.41.
Cabaletta Bio (NASDAQ:CABA - Get Free Report ) last released its earnings results on Thursday, March 21st. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.07). Research analysts anticipate that Cabaletta Bio, Inc. will post -1.82 EPS for the current year.
Institutional Investors Weigh In On Cabaletta Bio A number of large investors have recently modified their holdings of the business. Perceptive Advisors LLC lifted its position in shares of Cabaletta Bio by 76.9% during the 4th quarter. Perceptive Advisors LLC now owns 2,003,058 shares of the company's stock worth $45,469,000 after buying an additional 870,567 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Cabaletta Bio by 14.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,968,108 shares of the company's stock valued at $29,955,000 after purchasing an additional 246,596 shares in the last quarter. Redmile Group LLC grew its holdings in shares of Cabaletta Bio by 29.5% during the 3rd quarter. Redmile Group LLC now owns 1,774,252 shares of the company's stock valued at $27,004,000 after purchasing an additional 403,953 shares during the last quarter. Jennison Associates LLC grew its holdings in shares of Cabaletta Bio by 14.4% during the 4th quarter. Jennison Associates LLC now owns 1,626,628 shares of the company's stock valued at $36,924,000 after purchasing an additional 204,261 shares during the last quarter. Finally, Wellington Management Group LLP increased its position in Cabaletta Bio by 119.0% during the 4th quarter. Wellington Management Group LLP now owns 539,876 shares of the company's stock worth $12,255,000 after purchasing an additional 293,306 shares in the last quarter.
About Cabaletta Bio (
Get Free Report )
Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.
Further Reading This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cabaletta Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cabaletta Bio wasn't on the list.
While Cabaletta Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
